Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression

Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression

Abstract Background Molecular mechanisms driving acquired resistance to anti-EGFR therapies in metastatic colorectal cancer (mCRC) are complex but generally involve the activation of the downstream RAS-RAF-MEK-MAPK pathway. Nevertheless, even if inhibition of EGFR and MEK could be a strategy for ove...

Full description

Bibliographic Details
Main Authors: S. Napolitano, N. Matrone, A. L. Muddassir, G. Martini, A. Sorokin, V. De Falco, E. F. Giunta, D. Ciardiello, E. Martinelli, V. Belli, M. Furia, S. Kopetz, F. Morgillo, F. Ciardiello, T. Troiani
Format: Article
Language:English
Published: BMC 2019-12-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Colorectal cancer
MEK inhibitor resistance
PD-L1 inhibitors
Online Access:https://doi.org/10.1186/s13046-019-1497-0

Internet

https://doi.org/10.1186/s13046-019-1497-0

Similar Items